Measures semaglutide concentration in cerebrospinal fluid after treatment in Alzheimer's patients, indicating potential benefits.
To measure the concentration of semaglutide in the cerebrospinal fluid (CSF) of patients with early Alzheimer’s disease (AD) after 12 weeks’ treatment.
No takes yet. Share an insight, caveat, or question.
Alford et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: